Čájehuvvojit 1 - 8 oktiibuot 8 bohtosis ohcui Donna Neuberg (15038318)', ohcanáigi: 0,01s Aiddostahte ozu
  1. 1
    Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer

    Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer Dahkki Christopher J. Gibson (15907642)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer

    Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer Dahkki Christopher J. Gibson (15907642)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: